CA2478239A1 - The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents - Google Patents

The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents Download PDF

Info

Publication number
CA2478239A1
CA2478239A1 CA002478239A CA2478239A CA2478239A1 CA 2478239 A1 CA2478239 A1 CA 2478239A1 CA 002478239 A CA002478239 A CA 002478239A CA 2478239 A CA2478239 A CA 2478239A CA 2478239 A1 CA2478239 A1 CA 2478239A1
Authority
CA
Canada
Prior art keywords
integrin
cancer
vitaxin
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478239A
Other languages
English (en)
French (fr)
Inventor
Richard Woessner
Peter Kiener
Melissa Dormitzer
William Walsh
Jon Heinrichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478239A1 publication Critical patent/CA2478239A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002478239A 2002-03-04 2003-03-04 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents Abandoned CA2478239A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US36185902P 2002-03-04 2002-03-04
US60/361,859 2002-03-04
US37039802P 2002-04-05 2002-04-05
US60/370,398 2002-04-05
US44426503P 2003-01-30 2003-01-30
US60/444,265 2003-01-30
PCT/US2003/006684 WO2003075957A1 (en) 2002-03-04 2003-03-04 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Publications (1)

Publication Number Publication Date
CA2478239A1 true CA2478239A1 (en) 2003-09-18

Family

ID=27808630

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478239A Abandoned CA2478239A1 (en) 2002-03-04 2003-03-04 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Country Status (6)

Country Link
US (2) US20040001835A1 (https=)
EP (1) EP1487492A4 (https=)
JP (1) JP2005533001A (https=)
AU (2) AU2003217930A1 (https=)
CA (1) CA2478239A1 (https=)
WO (1) WO2003075957A1 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
ES2342461T3 (es) 2003-10-17 2010-07-07 Oy Neurofood Ab Agente de estroncio no radiactivo para tratar el cancer.
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
BRPI0706540A2 (pt) * 2006-01-18 2011-03-29 Merck Patent Gmbh terapia especìfica usando ligantes de integrina para tratar cáncer
US20110165150A1 (en) * 2006-01-18 2011-07-07 Merck Patent Gmbh Isolated organ perfusion combination therapy of cancer
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
AU2009233322B2 (en) 2008-03-31 2014-04-17 Council Of Scientific & Industrial Research A tumor model system useful to study multistage cancer
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
CN102597001B (zh) * 2009-08-19 2014-07-30 默克专利有限公司 在ffpe材料中用于检测整联蛋白复合体的抗体
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SG10201506782XA (en) 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
US20120164449A1 (en) * 2010-12-23 2012-06-28 Stephen Woodrow Foss Fibers with improving anti-microbial performance
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
CN103889453A (zh) * 2011-07-22 2014-06-25 鲍威尔·卡林斯基 肿瘤选择性趋化因子调节
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US9289468B2 (en) * 2011-09-16 2016-03-22 Beijing Sunbio Biotech Co. Ltd. Fusion protein comprising circularly permuted form of trail/Apo2L, coding gene and use thereof
US10598653B2 (en) 2011-11-01 2020-03-24 Bionomics Inc. Methods of blocking cancer stem cell growth
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
EP3539985A1 (en) 2012-02-24 2019-09-18 AbbVie Stemcentrx LLC Anti sez6 antibodies and methods of use
BR112014020826A8 (pt) 2012-02-24 2017-09-19 Stem Centrx Inc Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco – anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
US9234007B2 (en) 2012-07-02 2016-01-12 University Of South Florida RGD mimetic γ-AApeptides and methods of use
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
CN105792836A (zh) 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
US9645155B2 (en) 2013-08-28 2017-05-09 University Of South Florida Methods of synthesizing γ-aapeptides, γ-aapeptide building blocks, γ-aapeptide libraries, and γ-aapeptide inhibitors of Aβ40 aggregates
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
CA2939941A1 (en) 2014-02-21 2015-08-27 Abbvie Stemcentrx Llc Anti-dll3 antibodies and drug conjugates for use in melanoma
CA2944649C (en) 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство
WO2017161414A1 (en) 2016-03-22 2017-09-28 Bionomics Limited Administration of an anti-lgr5 monoclonal antibody
MX2019011717A (es) * 2017-03-31 2019-12-16 Univ California Composiciones y metodos para focalizar y matar celulas madre positivas a cancer alfa-v beta-3 y tratar cancer resistentes a farmacos.
JP7699542B2 (ja) 2018-11-20 2025-06-27 コーネル ユニバーシティー 放射線核種の大環状錯体およびがんの放射線療法におけるそれらの使用
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
KR102304832B1 (ko) * 2020-08-12 2021-09-24 영남대학교 산학협력단 암 세포의 증식을 억제하는 펩티드 fnin3 및 이의 용도
JP7439808B2 (ja) * 2021-09-17 2024-02-28 株式会社プロテリアル 断線検知方法および断線検知装置
EP4554619A1 (en) 2022-07-15 2025-05-21 Danisco US Inc. Methods for producing monoclonal antibodies
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US5306620A (en) * 1987-07-08 1994-04-26 The Scripps Research Institute Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5149780A (en) * 1988-10-03 1992-09-22 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
CA2000048A1 (en) * 1988-10-03 1990-04-03 Edward F. Plow Peptides and antibodies that inhibit integrin-ligand bindin g
US5498694A (en) * 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
US5196511A (en) * 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5830678A (en) * 1990-10-30 1998-11-03 Fred Hutchinson Cancer Research Center Method for identifying a target peptide that modulates the binding of epinectin ligand to integrin receptors
US5773574A (en) * 1990-12-03 1998-06-30 The Scripps Research Institute Polypeptides for promoting cell attachment
CA2108451A1 (en) * 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
US5310874A (en) * 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
US5190873A (en) * 1991-06-21 1993-03-02 California Institute Of Biological Research Hybrid tryptophan aporepressor containing ligand binding sites
WO1993020229A1 (en) * 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US5478725A (en) * 1992-06-12 1995-12-26 University Of Pennsylvania αv β3 integrin as a predictor of endometriosis
ATE250138T1 (de) * 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
US5705481A (en) * 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5523209A (en) * 1994-03-14 1996-06-04 The Scripps Research Institute Methods for identifying inhibitors of integrin activation
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE4415310A1 (de) * 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
EP0719859B1 (en) * 1994-12-20 2003-07-02 MERCK PATENT GmbH Anti-alpha V-integrin monoclonal antibody
US5681820A (en) * 1995-05-16 1997-10-28 G. D. Searle & Co. Guanidinoalkyl glycine β-amino acids useful for inhibiting tumor metastasis
SG68529A1 (en) * 1995-05-25 1999-11-16 Univ Singapore The use of des-aspartate-angiotensin i (agr-val-tyr-ile-his-pro-phe-his-leu) as an anti-cardiac hypertrophic agent
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US5767071A (en) * 1995-06-07 1998-06-16 Ixsys Incorporated Sevenmer cyclic peptide inhibitors of diseases involving αv β3
US5780426A (en) * 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5874562A (en) * 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US6100423A (en) * 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US5817457A (en) * 1996-02-07 1998-10-06 Ma Bioservices, Inc. Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
WO1997036858A1 (en) * 1996-03-29 1997-10-09 G.D. Searle & Co. Cyclopropyl alkanoic acid derivatives
ES2160949T3 (es) * 1996-03-29 2001-11-16 Searle & Co Derivados de fenilen-sulfonamida sustituidos en meta.
DK0894084T3 (da) * 1996-03-29 2002-10-14 Searle & Co Kanelsyrederivater og deres anvendelse som integrinantagonister
DE69706407T2 (de) * 1996-03-29 2002-05-29 G.D. Searle & Co., Chicago META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
DE19613933A1 (de) * 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5925655A (en) * 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
US6211184B1 (en) * 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
US5952341A (en) * 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
IL129344A0 (en) * 1996-11-27 2000-02-17 Du Pont Pharm Co Novel integrin receptor antagonists
JP3721684B2 (ja) * 1997-01-07 2005-11-30 ブラザー工業株式会社 印字装置及びファクシミリ装置
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
US6193968B1 (en) * 1997-04-11 2001-02-27 The Burnham Institute Methods for using anti-αvβ3 integrin antibody
EP0973550B1 (en) * 1997-04-11 2002-10-09 G.D. SEARLE & CO. Antagonistic anti-avb3 integrin antibodies
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6294549B1 (en) * 1997-07-23 2001-09-25 Merck & Co., Inc. Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
US20020019387A1 (en) * 1997-09-24 2002-02-14 Smithkline Beecham Corporation Vitronectin receptor antagonist
CA2309204A1 (en) * 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists
JP3349935B2 (ja) * 1997-12-05 2002-11-25 アルプス電気株式会社 アクティブマトリクス型液晶表示装置
US6066648A (en) * 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
JP2003504301A (ja) * 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
KR100335348B1 (ko) * 1998-06-23 2002-05-06 김두식 종양 혈관신생 억제기능을 가지는 살모신을 유효성분으로 함유하는 항암제
AU748621B2 (en) * 1998-08-13 2002-06-06 Merck & Co., Inc. Integrin receptor antagonists
US6235877B1 (en) * 1999-08-04 2001-05-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
US6204282B1 (en) * 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
AU2592600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU747503B2 (en) * 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6344484B1 (en) * 1999-02-12 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Tyrosine alkoxyguanidines as integrin inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
CN1589145A (zh) * 1999-06-02 2005-03-02 麦克公司 αv整联蛋白受体拮抗剂
AU5379900A (en) * 1999-06-07 2000-12-28 Shire Biochem Inc. Thiophene integrin inhibitors
WO2000078317A1 (en) * 1999-06-23 2000-12-28 Merck & Co., Inc. Integrin receptor antagonists
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
US6849639B2 (en) * 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
CA2397194C (en) * 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
CA2397665A1 (en) * 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20020001840A1 (en) * 2000-04-03 2002-01-03 Carlos Lopez-Otin Methods and compositions for modulating integrin-mediated cell-cell interactions
WO2002022615A1 (en) * 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists

Also Published As

Publication number Publication date
JP2005533001A (ja) 2005-11-04
WO2003075957A1 (en) 2003-09-18
EP1487492A1 (en) 2004-12-22
US20040001835A1 (en) 2004-01-01
AU2009200666A1 (en) 2009-03-12
EP1487492A4 (en) 2008-10-01
AU2003217930A1 (en) 2003-09-22
US20090148459A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
CA2478239A1 (en) The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
AU2003273299B2 (en) Methods of preventing or treating cell malignancies by administering CD2 antagonists
US20050084489A1 (en) Methods of preventing or treating disorders by administering and integrin alphanubeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
US7371381B2 (en) Anti-galanin antibodies and uses thereof
US7604799B2 (en) EphA4 Antibodies
EP2422811A2 (en) Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20040091486A1 (en) EphA2 agonistic monoclonal antibodies and methods of use thereof
EP3461495A1 (en) Methods of improving or accelerating physical recovery after surgery for hip fracture
JP2006516636A (ja) 抗インテグリンαｖβ３抗体製剤及びその用途
JP4860477B2 (ja) ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
US20090053238A1 (en) Stabilized High Concentration Anti-Integrin alphavbeta3 Antibody Formulations
US20040208869A1 (en) Uses of anti-integrin alphanubeta3 antibody formulations
JP2009521219A (ja) 親和性最適化ＥｐｈＡ２アゴニスト抗体およびその使用法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued